Whole-exome sequencing reveals microsatellite DNA markers for response to dofetilide initiation in patients with persistent atrial fibrillation: A pilot study.

ABSTRACT:

Background

Dofetilide is a class III antiarrhythmic drug effective for the treatment of atrial fibrillation (AF). Dofetilide initiation (DI) associates with corrected QT interval (QTc) prolongation. Significant QTc prolongation during DI mandates dose adjustment or discontinuation of the drug. Microsatellite DNA are novel genetic markers associated with congenital and acquired health conditions.

Hypothesis

DNA microsatellite polymorphism may associate with QTc response to dofetilide initiation in patients with persistent AF.

Methods

We performed whole-exome sequencing in a cohort of patients with persistent AF undergoing DI. Electrocardiographic variables and clinical data were assessed. We defined patients as eligible for DI when no significant QTc prolongation (>20%

SUBMITTER: Kinney N 

PROVIDER: S-EPMC6489891 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature